IP Library Granted Patent US 11,541,119
Granted Patent B2
US 11,541,119 · App. 16/659,986 · Granted Jan 3, 2023

Tumor treatment methods using cells that localize to the tumor

Inventor: Vikas Kundra (Bethesda, MD)
Assignee: Vikas Kundra
A61K47/46A61K35/28A61K38/179A61K38/31A61K47/6425A61K47/6901A61K51/00A61K51/083A61K51/088C07K14/71C12N15/88
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,541,119
App. No.
16/659,986
Granted
Jan 3, 2023
Kind
B2
Abstract

Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.

Claims (16)

1. A method of treating a tumor, comprising the steps of:

a) providing cells comprising stem cells, progeny of stem cells, or fibroblasts, wherein the cells are capable of localizing to a tumor;

b) introducing the stem cells, progeny of stem cells or fibroblasts to a subject having a tumor wherein said introduced cells localize to the tumor; and

c) administering to the subject an anti-tumor radiotherapeutic or thermal therapeutic that binds the cells and effects a damage on the tumor.

2. The method of claim 1 , wherein the stem cells, the progeny of stem cells or the fibroblasts comprise a nucleic acid molecule, wherein the nucleic acid molecule or its encoded protein is capable of binding a radiotherapeutic or thermal therapeutic.

3. The method of claim 2 , wherein the stem cell, the progeny of stem cells or the fibroblasts comprise a nucleic acid encoding a protein sequence selected from the group consisting of a protein tag gene, a reporter gene, a therapeutic gene, a signaling sequence, and a trafficking sequence.

4. The method of claim 1 , wherein the stem cells, the progeny of stems cells or the fibroblasts comprise a nucleic acid molecule encoding a somatostatin receptor.

5. The method of claim 1 , wherein the stem cells are induced pluripotent stem cells, embryonic stem cells, somatic stem cells, germ stem cells, epidermal stem cells, and/or tissue-specific stem cells.

6. The method of claim 1 , wherein the stem cells are mesenchymal stem cells.

7. The method of claim 1 , wherein the stem cells are pluripotent stem cells.

8. The method of claim 1 , wherein an anti-tumor radiotherapeutic is administered to the subject.

9. The method of claim 8 , wherein the radiotherapeutic comprises a therapeutic radionuclide.

10. The method of claim 9 , wherein the therapeutic radionuclide is a β − particle emitter.

11. The method of claim 10 , wherein the therapeutic radionuclide comprises 177 Lu or 90 Y.

12. The method of claim 1 , wherein a thermal therapeutic is administered to the patient.

13. The method of claim 1 , wherein the tumor is neuroendocrine tumor, breast tumor, lung tumor, prostate tumor, ovarian tumor, brain tumor, liver tumor, cervical tumor, colon tumor, renal tumor, skin tumor, head and neck tumor, bone tumor, esophageal tumor, bladder tumor, uterine tumor, lymphatic tumor, stomach tumor, pancreatic tumor, testicular tumor, or lymphoma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2023
From: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
To: KUNDRA, VIKAS
Reel/Frame 062869/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2022
From: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
To: KUNDRA, VIKAS
Reel/Frame 061930/0354 →
Continuity (4)
Division 15647840 · Jul 12, 2017
Division 13821541
Provisional Application 61380920 · Sep 8, 2010
Related Publication 20200038512A1 · Feb 6, 2020